|
Allele Symbol Allele Name Allele ID |
Tg(tetO-Vegfa)90Ala transgene insertion 90, Ann L Akeson MGI:3586336 |
||||||||||||||||||||||||||||||||
| Summary |
7 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• local bone and marrow tissue in doxycycline-treat mice are replaced with massively enlarged vascular structures (hemangiomas) unlike in wild-type mice
|
| N |
• doxycycline-treat mice exhibit normal bone density, osteoclastic bone remodeling, and bone degradation
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• doxycycline-treated mice exhibit a increase metaphyseal microvascular density compared to in wild-type mice
|
|
• following doxycycline treatment for the first 2 weeks of life, growing long bones are abnormal in shape and morphology with abundant stromal cells and blood vessels surrounding numerous trabeculae unlike in wild-type mice
• adult mice treated with doxycycline for 14 days exhibit disrupted bone architecture with abundant peritrabecular mesenchymal stromal cells in the metaphyseal and epiphyseal regions compared with wild-type mice
• adult mice treated with doxycycline for 14 days exhibit lamellar cortical bone is replaced with trabecular-like porous bone structure with abundant intercalating mesenchymal tissue components and osteoclast-rich remodelling units unlike in wild-type mice
|
|
• doxycycline-treated mice exhibit reduced osteoclast numbers in regions of excessive bone and vascularization compared with wild-type mice
• however, osteoclast coverage and bone remodeling are normal in the cortical regions of bone following doxycycline treatment
|
|
• in doxycycline-treated mice, bone marrow blood vessels exhibit hemangioma-like morphology and are filled with erythrocytes unlike in wild-type mice
• in doxycycline-treated mice, hematopoietic bone marrow is replaced with new bone, marrow fibrosis, and aberrant blood vessels displaying paucity of myeloid cells unlike in wild-type mice
|
|
• doxycycline-treated mice exhibit bone marrow fibrosis unlike in wild-type mice
|
|
• adult mice treated with doxycycline for 14 days exhibit a 70% increase in trabecular density compared with wild-type mice
|
|
• adult mice treated with doxycycline for 14 days exhibit increased metaphyseal trabecular bone mass compared with wild-type mice
|
|
• at E16.5, doxycycline-treated mice exhibit increased cell proliferation in the perichondrium/periosteum and throughout the primary ossification center compared with wild-type mice
• adult mice treated with doxycycline exhibit increased proliferation of the mesenchymal cells in the metaphysis, epiphysis, and periosteum compared with wild-type mice
|
|
• in doxycycline-treated mice as determined by marker expression
|
|
• doxycycline-treated mice exhibit a increase in growth plate mineralization compared to in wild-type mice
|
|
• doxycycline-treated mice exhibit a mild decrease in growth plate thickness compared to in wild-type mice
|
|
• increased following doxycycline treatment
|
|
• doxycycline-treated mice exhibit reduced bone resorption in the diaphyses and metaphysis compared with wild-type mice
• however, osteoclast coverage and bone remodeling are normal in the cortical regions of bone following doxycycline treatment
|
|
• doxycycline-treated mice exhibit an increase in CFU-Cs (colony-forming units in culture) in the peripheral blood and spleen compared with wild-type mice
• however, bone marrow CFUs of doxycycline-treated mice are normal
|
|
• in 25% of doxycycline-treated mice indicating extramedullary hematopoiesis
|
|
• as indicated by enlarged spleen size in 25% of doxycycline-treated mice
|
|
• in the spleen of doxycycline-treated mice
|
|
• the number of megakarypcyte and progenitor cells in the spleens of doxycycline-treated mice is increased compared to in wild-type mice
|
|
• small after 2 weeks of doxycycline treatment
|
|
• doxycycline-treated mice exhibit reduced osteoclast numbers in regions of excessive bone and vascularization compared with wild-type mice
• however, osteoclast coverage and bone remodeling are normal in the cortical regions of bone following doxycycline treatment
|
|
• in the peripheral blood of doxycycline-treated mice
|
|
• following doxycycline treatment, bone vasculogenesis is increased compared to in wild-type mice
• in doxycycline treated mice, bone marrow blood vessels exhibit hemangioma-like morphology and are filled with erythrocytes unlike in wild-type mice
|
|
• in 25% of doxycycline-treated mice indicating extramedullary hematopoiesis
|
|
• doxycycline-treated mice exhibit reduced osteoclast numbers in regions of excessive bone and vascularization compared with wild-type mice
• however, osteoclast coverage and bone remodeling are normal in the cortical regions of bone following doxycycline treatment
|
|
• in doxycycline-treated mice as determined by marker expression
|
|
• in 25% of doxycycline-treated mice indicating extramedullary hematopoiesis
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• administration of doxycycline in the drinking water to 3-4 month old mice and consequent VEGF-A164 expression in all cell caused death in 3 out of 8 and moribund appearance in rest of animals after 5 days of treatment
|
|
• administration of doxycycline to pregnant dam starting at day E1.5 and consequent VEGF-A164 expression in all embryonic cell caused lethality at E9.5 with no primitive red blood cells in the developing yolk sac and abnormal blood island
|
|
• administration of doxycycline in the drinking water to 3-4 month old mice and consequent VEGF-A164 expression in all cell caused edema of the face, ears and feet after 2 days of treatment
|
|
• administration of doxycycline in the drinking water to 3-4 month old mice and consequent VEGF-A164 expression in all cell caused "peliosis-like" liver characterized by an extended blood filed enlarged hepatic sinusoids and a total disruption of the normal liver architecture and blood in the intestine after 5 days of treatment
|
|
• administration of doxycycline in the drinking water to 3-4 month old mice and consequent VEGF-A164 expression in all cell caused a decrease in cellularity and decreased size in thymus after 5 days of treatment
|
|
• administration of doxycycline in the drinking water to 3-4 month old mice and consequent VEGF-A164 expression in all cell caused enlarged lymph nodes after 5 days of treatment
|
|
• administration of doxycycline in the drinking water to 3-4 month old mice and consequent VEGF-A164 expression in all cell caused a decrease in cellularity and decreased size in thymus after 5 days of treatment
|
|
• administration of doxycycline in the drinking water to 3-4 month old mice and consequent VEGF-A164 expression in all cell caused erythema of the face, ears and feet after 2 days of treatment
|
|
• administration of doxycycline in the drinking water to 3-4 month old mice and consequent VEGF-A164 expression in all cell caused a decrease in cellularity and decreased size in thymus after 5 days of treatment
|
|
• administration of doxycycline in the drinking water to 3-4 month old mice and consequent VEGF-A164 expression in all cell caused "peliosis-like" liver characterized by an extended blood filed enlarged hepatic sinusoids and a total disruption of the normal liver architecture and blood in the intestine after 5 days of treatment
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• administration of doxycycline in the drinking water to 4 month old mice and consequent VEGF-A164 expression in podocyte of glomerulus caused proteinuria after 7 days of treatment
|
|
• administration of doxycycline in the drinking water to 4 month old mice and consequent VEGF-A164 expression in podocyte of glomerulus caused proteinuria after 7 days of treatment
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• administration of doxycycline to pregnant dam starting at day E1.5 and consequent VEGF-A164 expression in neural cell lineage caused vascular abnormalities by E12.5 associated with spinal cord and brain hemorrhages
|
|
• administration of doxycycline to pregnant dam starting at day E1.5 and consequent VEGF-A164 expression in neural cell lineage caused vascular abnormalities by E12.5 associated with spinal cord and brain hemorrhages
|
|
• administration of doxycycline to pregnant dam starting at day E1.5 and consequent VEGF-A164 expression in neural cell lineage caused vascular abnormalities by E12.5 associated with spinal cord and brain hemorrhages
|
|
• administration of doxycycline to pregnant dam starting at day E1.5 and consequent VEGF-A164 expression in neural cell lineage caused vascular abnormalities by E12.5 associated with spinal cord and brain hemorrhages
|
| N |
• administration of doxycycline in the drinking water to 3-4 month old mice and consequent VEGF-A164 expression in neural cell lineage did not cause obvious gross behavioral or phenotypic abnormalities in brain after 5 days of treatment
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• administration of doxycycline to pregnant mother and consequent VEGF-A164 expression in peripheral respiratory epithelial cells of E10.5 to E16.5 embryo caused altered peripheral lung morphogenesis with disrupted vascular pattern formation
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• administration of doxycycline to pregnant mother and consequent VEGF-A164 expression in conducting airway epithelial cells of E10.5 to E16.5 embryo caused irregular evagination of epithelium into the lumen of bronchi and bronchioli
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/23/2024 MGI 6.23 |
|
|
|
||
Analysis Tools